Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Acute Myeloid Leukemia (AML) in Adults
- Chemotherapy for Acute Myeloid Leukemia (AML)
- Targeted Therapy Drugs for Acute Myeloid Leukemia (AML)
- Non-Chemo Drugs for Acute Promyelocytic Leukemia (APL)
- Surgery for Acute Myeloid Leukemia (AML)
- Radiation Therapy for Acute Myeloid Leukemia (AML)
- Stem Cell Transplant for Acute Myeloid Leukemia (AML)
- Typical Treatment of Acute Myeloid Leukemia (Except APL)
- Treatment of Acute Promyelocytic Leukemia (APL)
- Treatment Response Rates for Acute Myeloid Leukemia (AML)
- If Acute Myeloid Leukemia (AML) Doesn’t Respond or Comes Back After Treatment
- If You Have Acute Myeloid Leukemia (AML)
Treatment Response Rates for Acute Myeloid Leukemia (AML)
The goal of treatment for acute myeloid leukemia (AML) is to put the leukemia into complete remission (where the bone marrow and blood cell counts return to normal), preferably a complete molecular remission (where there are no signs of leukemia in the bone marrow, even using sensitive lab tests), and to keep it that way.
Remission rates for most types of AML
About 2 out of 3 people with AML who get standard induction chemotherapy (chemo) go into remission. This usually means the bone marrow contains fewer than 5% blast cells, the blood cell counts return to within normal limits, and there are no signs or symptoms of the leukemia.
The chance of remission depends to a large part on a person’s specific prognostic factors, such as their age and health, and the presence of certain gene or chromosome changes in the leukemia cells.
For example, older people with AML generally don’t do as well as those who are younger. They often have trouble tolerating more intensive treatment, and they often have chromosome changes in their leukemia cells that are linked to a poorer outlook. About half of these people go into remission after initial treatment.
If the leukemia goes into remission, people typically get more chemo (consolidation) to try to get rid of any remaining leukemia cells. Up to half of people who get consolidation go into long-term remission (and may be cured). But this number is also affected by prognostic factors, such as a person’s age and health, and whether the leukemia cells have certain gene or chromosome changes. Getting an allogeneic stem cell transplant as consolidation is linked with a higher success rate, but it also has a higher risk of death as a complication.
Remission rates for acute promyelocytic leukemia (APL)
The outlook for people with acute promyelocytic leukemia (APL) tends to be better than for those with other types of AML, although again prognostic factors can be important. About 9 out of 10 people with APL will go into remission with standard induction treatment. With consolidation and maintenance, about 8 or 9 out of 10 people with APL stay in long-term remission.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Appelbaum FR. Chapter 95: Acute leukemias in adults. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2020.
Larson RA. Acute myeloid leukemia in younger adults: Post-remission therapy. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/acute-myeloid-leukemia-in-younger-adults-post-remission-therapy on June 5, 2024.
Larson RA. Initial treatment of acute promyelocytic leukemia in adults. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/initial-treatment-of-acute-promyelocytic-leukemia-in-adults on June 5, 2024.
Larson RA. Treatment of relapsed or refractory acute promyelocytic leukemia in adults. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-relapsed-or-refractory-acute-promyelocytic-leukemia-in-adults on June 5, 2024.
National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia. V.3.2024. Accessed at https://www.nccn.org on June 5, 2024.
Last Revised: June 6, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.